Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $64.00

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) had its price target boosted by research analysts at Bank of America from $63.00 to $64.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Bank of America's price target would indicate a potential upside of 25.44% from the company's current price.

AKRO has been the topic of a number of other research reports. HC Wainwright raised their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. UBS Group raised their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Citigroup cut their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Finally, Canaccord Genuity Group raised their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $82.50.

Akero Therapeutics Trading Up 6.2%

Shares of AKRO traded up $2.99 during mid-day trading on Tuesday, reaching $51.02. The company had a trading volume of 3,235,396 shares, compared to its average volume of 979,958. The stock has a market cap of $4.07 billion, a price-to-earnings ratio of -13.61 and a beta of -0.12. The firm has a fifty day simple moving average of $41.21 and a 200-day simple moving average of $38.73. Akero Therapeutics has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. On average, sell-side analysts anticipate that Akero Therapeutics will post -3.99 EPS for the current fiscal year.

Insider Activity

In other Akero Therapeutics news, VP Patrick Lamy sold 4,000 shares of the business's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $50.00, for a total transaction of $200,000.00. Following the completion of the transaction, the vice president now directly owns 33,492 shares of the company's stock, valued at $1,674,600. The trade was a 10.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jonathan Young sold 50,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $44.86, for a total transaction of $2,243,000.00. Following the transaction, the chief operating officer now directly owns 201,147 shares of the company's stock, valued at $9,023,454.42. The trade was a 19.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 223,208 shares of company stock valued at $9,313,294. Company insiders own 7.94% of the company's stock.

Institutional Trading of Akero Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AKRO. Northwest & Ethical Investments L.P. acquired a new position in Akero Therapeutics in the 1st quarter valued at approximately $32,000. GF Fund Management CO. LTD. acquired a new position in Akero Therapeutics in the 4th quarter valued at approximately $41,000. Sterling Capital Management LLC increased its stake in Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock valued at $50,000 after buying an additional 1,582 shares during the period. PNC Financial Services Group Inc. increased its stake in Akero Therapeutics by 30.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after buying an additional 390 shares during the period. Finally, Quarry LP acquired a new position in Akero Therapeutics in the 4th quarter valued at approximately $83,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.